

## REVIEW

# Recent insights into peroxisome biogenesis and associated diseases

Yukio Fujiki<sup>1,\*</sup>, Yuichi Abe<sup>1,†</sup>, Yuuta Imoto<sup>1,§</sup>, Akemi J. Tanaka<sup>2</sup>, Kanji Okumoto<sup>3</sup>, Masanori Honsho<sup>1,\*</sup>, Shigehiko Tamura<sup>4</sup>, Non Miyata<sup>5</sup>, Toshihide Yamashita<sup>6</sup>, Wendy K. Chung<sup>2</sup> and Tsuneyoshi Kuroiwa<sup>7</sup>

## ABSTRACT

Peroxisomes are single-membrane organelles present in eukaryotes. The functional importance of peroxisomes in humans is represented by peroxisome-deficient peroxisome biogenesis disorders (PBDs), including Zellweger syndrome. Defects in the genes that encode the 14 peroxins that are required for peroxisomal membrane assembly, matrix protein import and division have been identified in PBDs. A number of recent findings have advanced our understanding of the biology, physiology and consequences of functional defects in peroxisomes. In this Review, we discuss a cooperative cell defense mechanisms against oxidative stress that involves the localization of BAK (also known as BAK1) to peroxisomes, which alters peroxisomal membrane permeability, resulting in the export of catalase, a peroxisomal enzyme. Another important recent finding is the discovery of a nucleoside diphosphate kinase-like protein that has been shown to be essential for how the energy GTP is generated and provided for the fission of peroxisomes. With regard to PBDs, we newly identified a mild mutation, Pex26-F51L that causes only hearing loss. We will also discuss findings from a new PBD model mouse defective in Pex14, which manifested dysregulation of the BDNF–TrkB pathway, an essential signaling pathway in cerebellar morphogenesis. Here, we thus aim to provide a current view of peroxisome biogenesis and the molecular pathogenesis of PBDs.

**KEY WORDS:** Peroxisome, Oxidative stress, VDAC2, BAK, Nucleoside diphosphate kinase family, Peroxisome biogenesis disorder, BDNF, TrkB

## Introduction

The peroxisome is a ubiquitous, single-membrane-bounded intracellular organelle present in almost all, if not all, eukaryotes. It is classically defined as a subcellular organelle containing catalase and at least one hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-producing oxidase (de Duve and Baudhuin, 1966). Peroxisome functions in the catabolism of a

wide variety of substrates such as fatty acids, D-amino acids, L- $\alpha$ -hydroxy acids, uric acid and polyamine. Several human genetic disorders linked to an apparent absence of peroxisomes appear to be related to various biochemical dysfunctions. It is also known that the peroxisome plays crucial metabolic roles, including the catabolism of very long chain fatty acids through the  $\beta$ -oxidation system, biosynthesis of ether-linked glycerolipids, such as plasmalogens, metabolism of cholesterol and phytanic acid, and synthesis of bile acids (Heymans et al., 1983; Moser, 1987). Among these disorders related to peroxisome dysfunction, cerebro-hepato-renal syndrome (Zellweger syndrome) is a typical, severe disease (Goldfischer and Reddy, 1984; Zellweger et al., 1988). Many lines of biochemical and morphological evidence are consistent with the idea that peroxisomes are formed by division of pre-existing peroxisomes after post-translational import of newly synthesized proteins (see Lazarow and Fujiki, 1985; Borst, 1986 for reviews). These oxidative metabolic pathways produce H<sub>2</sub>O<sub>2</sub>, which is subsequently decomposed *in situ* by peroxisomal catalase. The importance of peroxisomal function is highlighted by fatal human genetic peroxisomal biogenesis disorders (PBDs), including Zellweger spectrum disorders (ZSDs), which account for ~80% of the patients with PBDs, including Heimler syndrome (Ratbi et al., 2015) and rhizomelic chondrodysplasia punctata (RCDP) (Weller et al., 2003). PBD patients manifest progressive metabolic disease, as well as developmental abnormalities that produce distinct dysmorphic features, including abnormal morphology of the central nervous system (CNS) (Berger et al., 2016). ZSDs comprise the most severe Zellweger syndrome (or cerebro-hepato-renal syndrome) (Goldfischer et al., 1973), the less severe neonatal adrenoleukodystrophy (NALD), and milder infantile Refsum disease (IRD) (Weller et al., 2003). Mutations in five different genes have been linked to RCDPs (Waterham et al., 2016; Honsho and Fujiki, 2017), including RCDP type 1 (RCDP1) with a deficiency in peroxisomal targeting signal 2 (PTS2)-transporter Pex7 (see below). Peroxisomal matrix proteins harbor either a peroxisomal targeting signal 1 (PTS1), which is a C-terminal SKL motif, or an N-terminal PTS2, which is the degenerate signal -R/KX5Q/HL, and are synthesized on free ribosomes in the cytosol and post-translationally transported to peroxisomes by the cytosolic receptors Pex5 or Pex7 (Fujiki, 2016; Platta et al., 2016) (Fig. 1). Inherited mutations in the genes encoding the peroxisomal enzymes essential for the synthesis of plasmalogens, including dihydroxyacetonephosphate acyltransferase, alkylglycerone phosphate synthase and fatty acyl-CoA reductase 1, cause RCDP types 2, 3, and 4, respectively, whereas a dysfunction of Pex7 and Pex5L, the longer form of Pex5, causes RCDP types 1 and 5, respectively (Waterham et al., 2016; Honsho and Fujiki, 2017).

Genetic heterogeneity comprising 14 complementation groups is found for PBDs, including ZSDs and RCDP1 (Matsumoto et al., 2003a; Thoms and Gaertner, 2012; Ebberink et al., 2012). To date, all of 14 genes responsible for these PBDs, called peroxin (*PEX*) genes, have been identified (Matsumoto et al., 2003a; Thoms and

<sup>1</sup>Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan.


<sup>2</sup>Department of Pediatrics, Columbia University Medical Center, New York, New York 10019, USA. <sup>3</sup>Department of Biology, Kyushu University, 744 Motoooka Nishi-ku, Fukuoka 819-0395, Japan. <sup>4</sup>Faculty of Arts and Science, Kyushu University, 744 Motoooka Nishi-ku, Fukuoka 819-0395, Japan. <sup>5</sup>Chemistry, Faculty of Sciences, Kyushu University, 744 Motoooka Nishi-ku, Fukuoka 819-0395, Japan.

<sup>6</sup>Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871. <sup>7</sup>Department of Chemical and Biological Science, Faculty of Science, Japan Women's University, 2-8-1 Mejirodai, Bunkyo-ku, Tokyo 112-8681, Japan.

\*Present address: Institute of Rheological Function of Food, Hisayama-chou, Fukuoka 811-2501, Japan. †Present address: Faculty of Arts and Science, Kyushu University, 744 Motoooka Nishi-ku, Fukuoka 819-0395, Japan. §Present address: Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

†Author for correspondence (yfujiki@kyudai.jp)

Y.F., 0000-0002-8138-6376



**Fig. 1. A schematic view of peroxisome biogenesis in mammalian cells.** Overview of the subcellular localization and molecular characteristics of peroxins. Peroxins are classified into three groups: (i) those, including Pex3, Pex16 and Pex19, which are responsible for peroxisome membrane assembly through the class I and class II pathways; (ii) those required for matrix protein import; and (iii) the different isoforms of Pex11, such as Pex11 $\alpha$ , Pex11 $\beta$ , and Pex11 $\gamma$ , that are involved in peroxisome division, together with DLP1, Mff and Fis1. (i) In membrane protein assembly, the cytoplasmic protein Pex19 binds and transports peroxisomal membrane proteins to the membrane-anchoring site Pex3 (class I pathway), and Pex16 functions as the receptor for Pex19 complexes with newly synthesized Pex3 (class II pathway). (ii) For matrix protein import, PTS1- and PTS2-containing matrix proteins are recognized in the cytoplasm by Pex5 and Pex7, respectively (step 1). PTS1 proteins are transported to peroxisomes by homo- and hetero-oligomers of Pex5S and Pex5L; there, Pex14 functions as a convergent, initial docking site of the 'protein import machinery' translocon (step 2). The Pex5L–Pex7–PTS2 complex is then recruited to Pex14 (in complex with Pex13) in the peroxisomal membrane, and the PTS1 and PTS2 cargo proteins are released either at the inner surface and/or the inside of peroxisomes (step 3), downstream of Pex14 and upstream of Pex13. Pex5 and Pex7 subsequently interact with the RING-containing peroxins, Pex2, Pex10 and Pex12, in the membrane before they finally shuttle back to the cytosol (step 4). In the terminal step of matrix protein import, a complex between Pex1 and Pex6, which both have AAA ATPase activity, interact with Pex26 and catalyzes the export of Pex5; here, Cys-monoubiquitylation of Pex5 (Ub-Pex5) is a prerequisite for the exit of Pex5 from peroxisomes (step 5). In addition, in mammals, the cytosolic factor AWP1/ZFAND6 (p40) is involved in the export of Ub-Pex5. Exported Ub-Pex5 in the cytosol is deubiquitylated by the deubiquitylating enzyme USP9X and/or glutathione (GSH) for a next round of matrix protein import (step 6). (iii) Three forms of Pex11, Pex11 $\alpha$ , Pex11 $\beta$  and Pex11 $\gamma$ , are involved in peroxisome proliferation where DLP1, Mff and Fis1 coordinately function (see text). The figure is adapted and modified from Fujiki (2016).

Gaertner, 2012; Ebberink et al., 2012; Fujiki et al., 2014b; Fujiki, 2016; Waterham et al., 2016) (Table 1). Peroxins are classified into three groups: (1) Pex3, Pex16 and Pex19, which are essential for peroxisome membrane assembly via classes I and II pathways; (2) ten peroxins that are required for matrix protein import; and (3) the different isoforms of Pex11, namely Pex11 $\alpha$ , Pex11 $\beta$  and Pex11 $\gamma$ , which are involved in peroxisome division together with dynamin-like protein 1 (DLP1, also known as DNM1L), mitochondrial fission factor (Mff) and mitochondrial fission protein 1 (Fis1) (Fujiki, 2016; Platta et al., 2016; Farré et al., 2019) (Fig. 1). However, despite the identification of the peroxins, several aspects of peroxisome function remain incompletely understood, such as regulation of peroxisome number in cells and mechanistic insight to pathogenesis of ZSDs.

In this Review, we will address three important issues with regard to peroxisome function, including how peroxisomes counteract cellular oxidative stresses, how the GTP that is required for the division machineries of peroxisomes and mitochondria is generated, and what are the pathogenic mechanisms underlying PBDs.

### Peroxisomes counteract oxidative stress – cell death and survival against oxidative stress

Although reactive oxygen species (ROS) are formed as a natural by-product of normal metabolism of oxygen, oxidative stress occurs when the generation of ROS exceeds the capacity of antioxidant defense. Mitochondria are widely recognized as a source of ROS in animal cells, but peroxisomes are another source of ROS, as H<sub>2</sub>O<sub>2</sub> can be generated by peroxisomal oxidation, such as fatty-acid  $\beta$ -oxidation, and decomposed by catalase. We discuss below our serendipitous finding that the proapoptotic factor BAK (also known as BAK1) regulates subcellular localization of catalase, implying a strategy against oxidative cellular stresses.

### BAK mediates peroxisomal catalase export

In the 1990s, we isolated a peroxisome-deficient Chinese hamster ovary (CHO) cell mutant, ZP114, which was impaired in matrix protein import (Tateishi et al., 1997), but the underlying mechanism was unclear. Using a functional forward genetic screening strategy, we recently identified voltage-dependent anion-selective channel

**Table 1. Mammalian *PEX* genes involved in peroxisome biogenesis and responsible for peroxisome deficiency disorders**


Gene	CG <sup>a</sup>		PBD	CHO mutants	Ps-memb. biogenesis <sup>b</sup>	Peroxin	
	US/EU	Japan				(kDa)	Characteristics
<i>PEX1</i>	1	E	ZS, NALD*, IRD*	Z24, ZP107	+	143	AAA family
<i>PEX2</i>	10	F	ZS, IRD*	Z65	+	35	PMP, RING
<i>PEX3</i>	12	G	ZS	ZPG208	–	42	PMP, PMP-DP
<i>PEX5</i>	2		ZS, NALD	ZP105*, ZP139	+	68	PTS1 receptor, TPR family
<i>PEX6</i>	4(6)	C	ZS, NALD*	ZP92	+	104	AAA family
<i>PEX7</i>	11	R	RCDP	ZPG207	+	36	PTS2 receptor, WD motif
<i>PEX10</i>	7(5)	B	ZS, NALD		+	37	PMP, RING
<i>PEX11β</i> <sup>c</sup>	16		ZS		+	28	PMP
<i>PEX12</i>	3		ZS, NALD, IRD	ZP109	+	40	PMP, RING
<i>PEX13</i>	13	H	ZS, NALD*	ZP128	+	44	PMP, PTS1-DP, SH3
<i>PEX14</i>	15	K	ZS	ZP110	+	41	PMP, PTS1-DP, PTS2-DP
<i>PEX16</i>	9	D	ZS		–	39	PMP, PMP-DP
<i>PEX19</i>	14	J	ZS	ZP119	–	33	CAAX motif, PMP receptor
<i>PEX26</i>	8	A	ZS, NALD*, IRD*	ZP124, ZP167	+	34	PMP, Pex1p-Pex6p recruiter

\*Temperature-sensitive phenotype. <sup>a</sup>Complementation group; <sup>b</sup>peroxisomal membrane assembly is normal (+) or impaired (–); <sup>c</sup>besides *PEX11β*, genes including *DLP1*, *Mff*, *Fis1* and *GDAP1* are also involved in fission process of peroxisome (see text). DP, docking protein; PMP, peroxisome membrane protein; TPR, tetratricopeptide repeat. For a review on the cloning of *PEX* genes, see Waterham and Ebberink (2012).

protein 2 (VDAC2) as being responsible for the defect in peroxisome biogenesis in the mutant cell ZP114 (Hosoi et al., 2017), in which the pro-apoptotic Bcl-2 protein BAK accumulates to remnants of peroxisomal membranes. We then attempted to delineate the role of BAK in peroxisome biogenesis. Knockdown (KD) of *BAK* or overexpression of the BAK inhibitors *BCL-X<sub>L</sub>* (the large isoform encoded by *BCL2L1*) and *MCL-1* restored the impaired peroxisome biogenesis in ZP114 cells, indicating that in the absence of VDAC2, BAK is sequestered from mitochondria to peroxisomes, where it induces their permeabilization, thereby giving rise to peroxisome deficiency (Hosoi et al., 2017). In normal cells, including CHO-K1 cells under normal conditions, catalase is mainly localized in peroxisomes, but some is also present in the cytosol (Baudhuin et al., 1964; Hosoi et al., 2017). Surprisingly, in *BAK*-KD wild-type CHO-K1 cells, the amount of cytosolic catalase was significantly and specifically reduced, suggesting that BAK is involved in cytosolic localization of catalase. Conversely, activation of BAK in CHO-K1 cells by overexpression of either one of the pro-apoptotic BH3-only proteins PUMA or BIM (also known as BBC3 and BCL2L11, respectively), but not BAD, released catalase from peroxisomes (Hosoi et al., 2017). Collectively, these findings strongly suggest that BAK localizes to peroxisomes and regulates peroxisome membrane permeability and catalase export (Fujiki et al., 2017; Hosoi et al., 2017) (Fig. 2). Such a mechanism underlying the subcellular localization of catalase has been further discussed in a spotlight article (Chipuk and Luna-Vargas, 2017).

Under intolerable cellular stress, such as oxidative stress, cells commit to apoptosis by compromising the integrity of the mitochondrial outer membrane, so-called mitochondrial outer membrane permeabilization (MOMP) (Wang, 2001; Newmeyer and Ferguson-Miller, 2003; Tait and Green, 2010). MOMP leads to the release of intermembrane-space proteins, including cytochrome *c*, followed by activation of caspases, which are responsible for the progression of apoptosis (Wang, 2001; Newmeyer and Ferguson-Miller, 2003; Tait and Green, 2010). The BCL-2 family proteins regulate apoptosis by controlling MOMP (Czabotar et al., 2014). Within the mitochondrial pathway of apoptosis, VDAC2 controls both the localization and proapoptotic activity of BAK. A potentially prosurvival mechanism that is characterized by permeabilization of the peroxisome membrane to release catalase

thus contrasts with commitment of the cell to the mitochondrial pathway of apoptosis by promoting cytochrome *c* release. Thus BAK-dependent membrane permeabilization is shared between mitochondria and peroxisomes, but with different outcomes. The



**Fig. 2. BAK-dependent control of catalase release from peroxisomes.** BAK is mostly localized at the mitochondrial outer membrane (MOM) where it is kept in an inactivated state by forming a complex with VDAC2 (left). Once BAK is activated upon apoptotic stimuli, it induces MOM permeabilization (MOMP) to release apoptogenic factors such as cytochrome *c*, which commit cells to undergoing apoptosis. A portion of the cellular pool of BAK is localized to peroxisomes in normal cells, where it controls the permeability of the peroxisomal membrane, leading to release of catalase to the cytosol (right). BAK-dependent membrane permeabilization is thus a mechanism that is shared between mitochondria and peroxisomes. Bona fide cytosolic catalase and the catalase released from peroxisomes through the BAK pore eliminate  $H_2O_2$ , a major causative of the oxidative stress, in the cytosol. The figure is adapted and modified from Fujiki et al. (2017) (<https://www.tandfonline.com/>).

catalase that is released from peroxisomes through the BAK pore potentially eliminates H<sub>2</sub>O<sub>2</sub>, a major causative of the oxidative stress, in the cytosol. We therefore proposed a novel and unique regulatory mechanism of peroxisomal biogenesis mediated by the BCL-2 family protein BAK, not BAX, that entails a regulation of the localization of peroxisomal matrix proteins through alterations in peroxisomal membrane permeability in response to various cellular stress signals, rather than the modulation of protein import machinery (Hosoi et al., 2017; Fujiki et al., 2017).

Catalase is imported into the peroxisome by the PTS1 receptor Pex5, which shuttles between the cytosol and peroxisomes to import peroxisomal matrix proteins harboring the PTS1 motif (Dammai and Subramani, 2001; Miyata and Fujiki, 2005; Platta et al., 2005). Pex5 has a highly conserved cysteine at position 11, which is a redox-sensitive site of mono-ubiquitylation that is essential for export of Pex5 to the cytosol (Carvalho et al., 2007; Platta and Erdmann, 2007; Okumoto et al., 2011). In the more reductive cytosol in peroxisome-deficient mutants compared to that of normal cells (Yano et al., 2010), cysteine 11 of Pex5 is less sensitive to the redox state; it becomes more stable, is highly susceptible to oxidants, such as oxidized glutathione, and is readily inhibited by oxidative stress (Apanasets et al., 2014). More recently, cysteine 11 of Pex5 has been suggested to act as a redox sensor and reduce the import of PTS1-containing proteins, especially catalase, under oxidative stress, which leads to the retention of catalase in the cytosol (Walton et al., 2017). Thus, it is likely that the release of catalase from peroxisomes mediated by BAK (Hosoi et al., 2017) and the inhibition of its import owing to defective ubiquitylation of cysteine 11 of Pex5 under oxidative stress (Apanasets et al., 2014) cooperatively contribute to the retention of catalase in the cytosol.

Further studies regarding the physiological roles of peroxisomal BAK and cytosolic catalase could help to delineate the mechanisms underlying the regulation of the localization of peroxisomal matrix proteins that are involved in peroxisome physiology and human disease.

### Morphogenesis of peroxisomes in mammals


Peroxisomes proliferate by growth and division (Lazarow and Fujiki, 1985; Thoms and Erdmann, 2005; Yan et al., 2005; Schrader and Fahimi, 2006; Fagarasanu et al., 2007; Honsho et al., 2016; Schrader et al., 2016). Peroxisomal division comprises three stages – elongation, constriction and fission – and involves Pex11β (Li and Gould, 2002), dynamin-like protein 1 (DLP1) (Li and Gould, 2003; Tanaka et al., 2006), mitochondrial fission factor (Mff) (Gandre-Babbe and van der Blik, 2008; Itoyama et al., 2013) and mitochondrial fission 1 (Fis1) (Koch et al., 2005; Kobayashi et al., 2007), all of which are localized to peroxisomes (Fig. 1; Table 1). Except for Pex11β, these factors are shared with mitochondria (Koch and Brocard, 2012; Schrader et al., 2012; Itoyama et al., 2013). Peroxisome fission is important for its normal function. Indeed, a human disorder with impaired DLP1 function has been reported (Waterham et al., 2007). The patient, a newborn girl, manifested microcephaly, abnormal brain development, optic atrophy and hypoplasia, with a defect of the fission of both mitochondria and peroxisomes, as well as a heterozygous, dominant-negative mutation in the *DLP1* gene (Waterham et al., 2007). A poly-unsaturated fatty acid of peroxisomal β-oxidation metabolites, docosahexaenoic acid (DHA, C22:6n-3), augments hyper-oligomerization of Pex11β and induces the elongation of peroxisomes, which leads to the fission stage in control fibroblasts, suggesting that a complex mechanism strictly regulates the peroxisome abundance to a constant level under normal conditions (Itoyama et al., 2012) (Fig. 3). Translocation of

DLP1, a member of the large GTPase family, from the cytosol to peroxisomes is a prerequisite for membrane fission. Mff is localized to peroxisomes, especially at the membrane-constricted regions of elongated peroxisomes (Itoyama et al., 2013). Knockdown of Mff abrogates the fission stage of peroxisomal division and leads to a failure to recruit DLP1 to peroxisomes. In contrast, ectopic expression of Mff elevates the peroxisomal targeting of DLP1 (Itoyama et al., 2013). Co-expression of Mff and Pex11β increases peroxisome abundance. Knockdown of Mff, but not Fis1, abolishes the DLP1–Pex11β interaction. Moreover, Pex11β interacts with Mff in a DLP1-dependent manner, suggesting that Mff plays a key role in the fission of the peroxisomal membrane in concert with Pex11β and DLP1 (Itoyama et al., 2013). A functional complex comprising Pex11β, Mff and DLP1 promotes Mff-mediated fission during peroxisomal division (Tanaka et al., 2006; Kobayashi et al., 2007; Delille et al., 2010; Koch et al., 2010; Itoyama et al., 2013; Yoshida et al., 2015). A patient with a homozygous non-sense mutation in the *PEX11B* (annotated by HUGO as *PEX11B*) gene has been reported, manifesting a defect of peroxisome division, but with apparently normal peroxisomal metabolism (Thoms and Gaertner, 2012; Ebberink et al., 2012). Another potential factor, ganglioside-induced differentiation-associated protein 1 (GDAP1) was suggested to be required for peroxisome fission, downstream of Pex11β and upstream of the fission steps mediated by Mff and DLP1 (Huber et al., 2013), inferring that GDAP1 mediates the interaction between Pex11β and the Mff–DLP1 complex. However, the regulatory mechanisms underlying peroxisomal division remain to be defined.

### The peroxisome and mitochondrion division machinery – role of the GTP provider DYNAMO

Peroxisomes and mitochondria proliferate by fission that is mediated by a dynamin-like GTPase, DLP1 or Dnm1 (Tanaka et al., 2006; Honsho et al., 2016). During the division of peroxisomes, a part of their membrane is pinched off by constriction of ring-shaped peroxisome-dividing (POD) machinery (Imoto et al., 2017). This constriction is mediated by the dynamin-like GTPase DLP1, which requires large amounts of GTP as an energy source. However, it is unknown where GTP is supplied from and how GDP is regulated. To search for factors involved in the regulation of DLP1, we attempted to isolate and perform proteomic analysis of the division machinery of peroxisomes. To that end, we made use of a unicellular red alga, *Cyanidioschyzon merolae*, which contains only a single peroxisome, mitochondrion and plastid per cell. In *C. merolae*, division of these organelles can be highly synchronized by stimulation with cycles of light and dark (Imoto et al., 2017). Using *C. merolae*, we recently identified a 17-kDa nucleoside diphosphate (NDP) kinase-like protein, we termed dynamin-based ring motive-force organizer 1 (DYNAMO1), as a fundamental component of both the mitochondrial division (MD) and POD machineries (Imoto et al., 2018). DYNAMO1 colocalizes with DLP1 on the division machineries and mediates the generation of GTP from ATP and GDP; this enzyme activity is essential to sustain DLP1-mediated fission of the mitochondrion and peroxisome (Imoto et al., 2018).

The POD machinery has a diameter of 50 to 600 nm and is composed of dynamin-based rings and skeletal filamentous rings formed at the cytoplasmic side of peroxisomal membranes (Imoto et al., 2013). A single or double dynamin-based ring-organizing center (DOC) is formed on the POD machinery (Imoto et al., 2017) and functions as the site where dynamin-based ring formation begins (Fig. 4). DOC-mediated dynamin-based ring formation also provides the basis for dynamin-based membrane division, including



**Fig. 3. Peroxisome morphogenesis in mammals.** A schematic model of division of peroxisomes in mammals is represented. DHA promotes the oligomerization of Pex11β, which leads to the formation of Pex11β-rich regions in the peroxisome membrane and initiates peroxisome elongation (step 1) in one direction (step 2). Mitochondrial fission factor 1 (Mff) and mitochondrial fission protein 1 (Fis1) localize to membrane-constricted regions of elongated peroxisomes, where Mff recruits dynamin-like protein 1 (DLP1) (step 3). The resulting complex comprising constitutively expressed Pex11β, Mff and DLP1 promotes Mff-mediated fission during peroxisomal division. Pex11α and Pex11γ can be also involved in this step (step 4). The complex may in addition include Fis1, which also interacts with DLP1. The DLP1 hydrolyzes GTP, which generates GDP and provides the energy needed to cleave peroxisomal membranes, resulting in peroxisomal fission (step 5). The figure is adapted and modified with permission from Springer Nature from Fujiki et al. (2014a).


mitochondrial division (Imoto et al., 2018), plastid division (Imoto et al., 2019) and most likely vesicle endocytosis in eukaryotes. Interestingly, more recently, we identified *C. merolae* DYNAMO2, an isoform of DYNAMO1, in the cytoplasm, which contains a highly conserved NDP kinase domain and may function as a potential regulator of cellular GTP levels during the cell cycle (Imoto et al., 2019).

NDP kinases of the NME family are highly conserved in eukaryotes and are involved in many different cellular processes. Based on the primary sequence similarity, nucleoside diphosphate kinase 3 (NME3) may be a potential ortholog of DYNAMO1. An interesting recent report described a homozygous mutation in the *NME3* gene in the patient with a fatal neurodegenerative disorder (Chen et al., 2019). The authors suggest that NME3 possesses two separate functions, the stimulation of mitochondrial fusion and NDP kinase activity, implying that both functions of NME3 might be involved in causing neuronal disorder (Chen et al., 2019). It would

be important to address whether NME3, which harbors a N-terminal hydrophobic segment as a putative membrane anchor, is located on peroxisomes and involved in peroxisome division. The effect of mutant NME3 on peroxisome morphogenesis will also need to be determined.

**A new phenotype of ZSD – a very mild mutation in the *PEX26* gene causes severe hearing loss**

Defects in *PEX* genes generally cause ZSD, which manifests in variable clinical phenotypes ranging from severe, lethal ZS to milder IRD. A number of phenotypes, including developmental delay, hypotonia, retinal dystrophy and sensorineural hearing loss, are commonly observed to varying degrees in patients with ZS, NALD and IRD (Weller et al., 2003). Defects in *PEX26* are responsible for ZSD of complementation group 8, one of the more common PBDs (Matsumoto et al., 2003a,b; Weller et al., 2005) (Table 1). By clinical exome sequencing, we recently identified an



**Fig. 4. Local GTP generation provides the constriction force for peroxisomal and mitochondrial division.** Initially, DYNAMO1 is recruited to the division site of the mitochondrion and peroxisome, together with DLP1 (phase 1, prophase), forming ring-shaped mitochondrial division (MD) and peroxisomal division (POD) machineries, respectively. Next, DYNAMO1 converts cytosolic ATP into GTP at the ring-like structures formed by the MD and POD machineries. Upon GTP generation, the DYNAMO1–DLP1 structure generates a strong motive force to constrict and pinch off the mitochondrion or peroxisome (phase 2). After fission, the MD and POD machineries containing DYNAMO1 and DLP1 are immediately disassembled (phase 3). The figure is adopted and modified from Imoto et al. (2018) where it was published under a CC-BY-4.0 license.

autosomal recessive missense mutation in the *PEX26* gene in a 19-year-old female of Ashkenazi Jewish pedigree with moderate to severe hearing loss (Tanaka et al., 2019). The mutation, c.153C>A (p.F51L) in *PEX26*, is homozygous in the proband and affected four siblings of seven, who share a phenotype of nonsyndromic sensorineural hearing loss with no other indications of ZSD. Pex26 is a C-tail-anchored type II membrane protein located in the peroxisomal membrane and recruits the AAA ATPase peroxins Pex1 and Pex6, which are essential for peroxisomal matrix protein import (Matsumoto et al., 2003a) (Fig. 1). The F51L mutation is located in the N-terminal region, close to the other mutations identified in patients with ZSD (Matsumoto et al., 2003a,b; Furuki et al., 2006; Waterham and Ebberink, 2012). Skin fibroblasts from this patient showed normal morphology and biogenesis of peroxisomes (Tanaka et al., 2019). However, the import rate of matrix proteins is significantly reduced and Pex26-F51L is unstable, and interacts less efficiently with Pex1–Pex6 complexes. Furthermore, in the fibroblasts of the patient, the level of DHA in plasmalogens is lowered, whereas other lipid metabolism processes, including peroxisomal fatty acid  $\beta$ -oxidation, are normal. Collectively, the F51L missense variant in *PEX26* causes only a mild defect in peroxisome biogenesis, which appears to lead to hearing loss (Tanaka et al., 2019). However, the molecular mechanism for how such a mild peroxisomal dysfunction with Pex26-F51L causes hearing loss remains to be defined.

It is noteworthy that potential links between peroxisomes and hearing loss have been previously reported. The *PJVK* gene encoding the gasdermin protein pejvakin (PJVK) is a causal gene of human autosomal recessive deafness (Delmagnani et al., 2015). Peroxisomal biogenesis is also known to be compromised in the cochlear cells of Persian families with hearing loss owing to a mutation *PJVK* gene, indicating that PJVK plays a role in regulating peroxisomal dynamics in cochlear cells of the inner ear (Delmagnani et al., 2015). Another study utilizing an exome sequencing approach identified biallelic mutations in *PEX1* and *PEX6* in six families diagnosed with Heimler syndrome, a rare recessive disease with varying manifestations including sensorineural hearing loss (Ratbi et al., 2015). This study also highlights the usefulness of highly efficient exome sequencing to


elucidate the pathogenesis in patients with defects in *PEX* genes, which may lead to the discovery of new functions of peroxisomes.

### Mechanisms underlying pathogenesis in PBDs – dysregulation of BDNF–TrkB signaling

PBDs manifest as neurological deficits in the central nervous system, including neuronal migration defects and abnormal cerebellum development. The biochemical abnormalities, including marked reduction of plasmalogens and accumulation of very long chain fatty acids (Weller et al., 2003), are thought to be relevant to the manifestation of malformations in the CNS. However, the mechanisms underlying pathogenesis remain enigmatic.

To elucidate the pathogenesis of ZSDs, mice with inactivation of *Pex2* (Faust and Hatten, 1997), *Pex5* (Baes et al., 1997) and *Pex13* (Maxwell et al., 2003) have been established. The resulting *Pex2*, *Pex5* or *Pex13* knockout (KO) mice survive *in utero*, but all die at a several hours to a few days after birth. The deletion of these individual *Pex* genes results in a complete deficiency of peroxisomal protein import, which gave rise to severe impairment of peroxisomal fatty acid oxidation and plasmalogen synthesis, as well as abnormal morphology of the CNS with neuronal migration defects (Baes et al., 1997; Faust, 2003; Maxwell et al., 2003), similar to the reported phenotypes in patients with ZSDs including Zellweger syndrome (Volpe and Adams, 1972; Evrard et al., 1978; Powers and Moser, 1998). *Pex7*-KO mice exhibit the abnormalities in plasmalogen biosynthesis, neuronal migration in cerebral cortex, and bone ossification, which are similar to those observed in the patients with RCDP1 (Brites et al., 2003). It is worth noting that *Pex11 $\beta$* -KO mice exhibit numerous pathological features of Zellweger syndrome, including a developmental delay, hypotonia, neuronal migration defects and enhanced neuronal apoptosis, even though they have no apparent defect in peroxisomal protein import and only mild defects in peroxisomal metabolic function, which is significantly different from patients and mice with Zellweger syndrome (Li et al., 2002).

As a step towards uncovering the pathological mechanisms underlying ZSDs, we recently established a new PBD mouse model that is defective in Pex14, termed the *Pex14 $\Delta$ C/ $\Delta$ C* mouse (Abe et al., 2018). The Pex14-defective mouse manifests neuronal migration defect in cerebral cortex, malformation of cerebellum and growth



**Fig. 5. A schematic model of abnormal dendritic development of Purkinje cells in the *Pex14 $\Delta$ C/ $\Delta$ C* mouse.** In the wild-type cerebellum (left), BDNF interacts with TrkB-TK+ on the surface of Purkinje cells. The cytosolic tyrosine kinase domain (TK) then undergoes autophosphorylation and activates MAPK–ERK and PI3K–AKT signaling, leading to dendritic arborization. In the *Pex14 $\Delta$ C/ $\Delta$ C* mouse, BDNF levels are increased around the Purkinje cells. On the Purkinje cells of the *Pex14 $\Delta$ C/ $\Delta$ C* mouse (right), the inactive receptor isoform TrkB-T1 is upregulated owing to increased alternative splicing and dominant-negatively inhibits autophosphorylation of TrkB-TK+. The reduced phosphorylation of TrkB-TK+ results in inability to activate MAPK–ERK and PI3K–AKT signaling, giving rise to an abnormal dendritic development of Purkinje cells. The figure is adopted and modified from Abe et al. (2018) where it was published under a CC-BY-4.0 license.

retardations, and died shortly after birth, while peroxisome biogenesis and metabolism were only partially defective. The *Pex14<sup>ΔC/ΔC</sup>* mouse shows an impaired dendritic development of Purkinje cells in cerebellum that is caused by a dysregulation of the brain-derived neurotrophic factor (BDNF)-TrkB pathway (Abe et al., 2018) (Fig. 5). In wild-type mouse cerebellum, BDNF binds to TrkB-TK<sup>+</sup>, an active form of BDNF receptor, on the Purkinje cells and activates extracellular signal-regulated kinase (ERK) and AKT signaling. In the *Pex14<sup>ΔC/ΔC</sup>* mouse, elevated levels of BDNF together with an enhanced expression of TrkB-T1, an inactive isoform of TrkB, dominant-negatively inhibit autophosphorylation of TrkB-TK<sup>+</sup>, and thus downstream ERK and AKT signaling, thereby resulting in the malformation of Purkinje cells (Abe et al., 2018) (Fig. 5). In the cerebellum of patients with Zellweger syndrome, impairment of the Purkinje cell arborization, heterotopia of Purkinje cells in the white matter and granule cell clustering between the Purkinje cells are observed (Volpe and Adams, 1972; Evrard et al., 1978; Powers and Moser, 1998). These phenotypes resemble those observed in mice with knockout of *Pex2* (Faust and Hatten, 1997), *Pex5* (Baes et al., 1997), *Pex13* (Maxwell et al., 2003) and *Pex14* (Abe et al., 2018), including the impairment of Purkinje cell arborization and granule cell migration defects, although the heterotopic Purkinje cells are not distinct in the *Pex2*-KO mice (Faust, 2003). During cerebellar development, the BDNF–TrkB signaling pathway plays pivotal roles in Purkinje cell arborization (Minichiello and Klein, 1996; Schwartz et al., 1997; Carter et al., 2002) and in granule cell migration from the external granular layer to the internal granular layer (Zhou et al., 2007). Heterotopic Purkinje cells are also observed in the patients with milder ZSDs, NALD and IRD, which show less severe defect of peroxisomal metabolism than the patients with Zellweger syndrome (Aubourg et al., 1986; Torvik et al., 1988). Therefore, the BDNF–TrkB signaling pathway in the cerebellum is most likely susceptible to the impaired peroxisomal metabolism in ZSDs. These findings provide for the first time an insight into the mechanism underlying the cerebellar pathogenesis in PBDs (Fig. 5). Addressing how peroxisomal dysfunction affects the elevation of BDNF and TrkB-T1 in the cerebellum will shed further light on the molecular mechanisms underlying the malformation of the cerebellum in PBDs.

## Perspectives

The studies discussed here clearly suggest that making use of different peroxin mutants in CHO cells and in cell lines from PBD patients, as well as *Pex* gene-KO mice can shed light on the molecular mechanisms underlying biogenesis and homeostasis of peroxisomes in organelle biology and pathogenesis of PBDs in human disease. We have highlighted here our recent insights into peroxisome biogenesis including fission, regulation of subcellular localization of catalase by BAK and the pathogenic mechanism underlying peroxisome-deficient diseases. Further studies addressing the physiological roles of peroxisomal BAK and cytosolic catalase might allow us to gain an understanding of how translocation of peroxisomal matrix proteins is regulated. Secondly, the generation and enrichment of local GTP and global GTP level are more likely regulated by DYNAMO1 and DYNAMO2, respectively, than by dynamin family members. However, it remains unclear how DYNAMO1 and DYNAMO2 regulate the supramolecular nanomachineries that influence the dynamic behavior of dynamin-regulated organelles, such as peroxisomes, mitochondria and other cellular structures. Furthermore, tackling the molecular basis of the specific phenotypes of *Pex* defects, such as how peroxisomal dysfunction mediated by knockout of *Pex14* upregulates of BDNF expression and abnormal

splicing, which results in a dominant-negative variant of TrkB in Purkinje cells in cerebellum, might also lead to a better understanding of the malfunctioning of other organs, such as liver, brain and kidney in PBDs. The outcome of these studies are likely to not only contribute to a better understanding of peroxisome physiology, but also of other intracellular compartments and associated diseases that involve organelle dysregulation.

## Note added in proof.

In regard to the elevation of BDNF expression in peroxisome-deficient cells, Abe et al. (Abe et al., 2020) very recently reported that cytosolic reductive states caused by a mislocalized catalase induce the elevation in BDNF secretion.

## Acknowledgements

We thank all of our colleagues and collaborators of the Fujiki laboratory who contributed to the work discussed in this Review.

## Competing interests

The authors declare no competing or financial interests.

## Funding

This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (JP24247038, JP25112518, JP25116717, JP26116007, JP15K14511 and JP17H03675) and grants from the Takeda Science Foundation and the Naito Foundation.

## References

- Abe, Y., Honsho, M., Itoh, R., Kawaguchi, R., Fujitani, M., Fujiwara, K., Hirokane, M., Matsuzaki, T., Nakayama, K., Ohgi, R. et al. (2018). Peroxisome biogenesis deficiency attenuates the BDNF–TrkB pathway-mediated development of the cerebellum. *Life Sci. Alliance* **1**, e201800062. doi:10.26508/lsa.201800062
- Abe, Y., Honsho, M., Kawaguchi, R., Matsuzaki, T., Ichiki, Y., Fujitani, M., Fujiwara, K., Hirokane, M., Oku, M., Sakai, Y. et al. (2020). A peroxisome deficiency-induced reductive cytosol state up-regulates the brain-derived neurotrophic factor pathway. *J. Biol. Chem.* **295**, 5321–5334. doi:10.1074/jbc.RA119.011989
- Apanasets, O., Grou, C. P., Van Veldhoven, P. P., Brees, C., Wang, B., Nordgren, M., Dodt, G., Azevedo, J. E. and Fransen, M. (2014). PEX5, the shuttling import receptor for peroxisomal matrix proteins, is a redox-sensitive protein. *Traffic* **15**, 94–103. doi:10.1111/tra.12129
- Aubourg, P., Scotto, J., Rocchiccioli, F., Feldmann-Pautrat, D. and Robain, O. (1986). Neonatal adrenoleukodystrophy. *J. Neurol. Neurosurg. Psychiatry*. **49**, 77–86. doi:10.1136/jnnp.49.1.77
- Baes, M., Gressens, P., Baumgart, E., Carmeliet, P., Casteels, M., Fransen, M., Evrard, P., Fahimi, D., Declercq, P. E., Collen, D. et al. (1997). A mouse model for Zellweger syndrome. *Nat. Genet.* **17**, 49–57. doi:10.1038/ng0997-49
- Baudhuin, P., Beaufay, H., Rahman-Li, Y., Sellinger, O. Z., Wattiaux, R., Jacques, P. and de Duve, C. (1964). Tissue Fractionation Studies 17. Intracellular distribution of monoamine oxidase, aspartate aminotransferase, alanine aminotransferase, D-amino acid oxidase and catalase in rat liver tissue. *Biochem. J.* **92**, 179–184.
- Berger, J., Dorninger, F., Forss-Petter, S. and Kunze, M. (2016). Peroxisomes in brain development and function. *Biochem. Biophys. Acta.* **1863**, 934–955. doi:10.1016/j.bbamcr.2015.12.005
- Borst, P. (1986). How proteins get into microbodies (peroxisomes, glyoxysomes, glycosomes). *Biochim. Biophys. Acta.* **866**, 179–203. doi:10.1016/0167-4781(86)90044-8
- Brites, P., Motley, A. M., Gressens, P., Mooyer, P. A. W., Ploegaert, I., Everts, V., Evrard, P., Carmeliet, P., Dewerchin, M., Schoonjans, L. et al. (2003). Impaired neuronal migration and endochondral ossification in *Pex7* knockout mice: a model for rhizomelic chondrodysplasia punctata. *Hum. Mol. Genet.* **12**, 2255–2267. doi:10.1093/hmg/ddg236
- Carter, A. R., Chen, C., Schwartz, P. M. and Segal, R. A. (2002). Brain-derived neurotrophic factor modulates cerebellar plasticity and synaptic ultrastructure. *J. Neurosci.* **22**, 1316–1327. doi:10.1523/JNEUROSCI.22-04-01316.2002
- Carvalho, A. F., Pinto, M. P., Grou, C. P., Alencastre, I. S., Fransen, M., Sá-Miranda, C. and Azevedo, J. E. (2007). Ubiquitination of mammalian Pex5p, the peroxisomal import receptor. *J. Biol. Chem.* **282**, 31267–31272. doi:10.1074/jbc.M706325200
- Chen, C.-W., Wang, H.-L., Huang, C.-W., Huang, C.-Y., Lim, W. K., Tu, I.-C., Koorapati, A., Hsieh, S.-T., Kan, S.-W., Tzeng, S.-R. et al. (2019). Two separate functions of NME3 critical for cell survival underlie a neurodegenerative disorder. *Proc. Natl. Acad. Sci. USA* **116**, 566–574. doi:10.1073/pnas.1818629116

- Chipuk, J. E. and Luna-Vargas, M. P. A.** (2017). The peroxisomes strike BAK: Regulation of peroxisome integrity by the Bcl-2 family. *J. Cell Biol.* **216**, 547-549. doi:10.1083/jcb.201701187
- Czabotar, P. E., Lessene, G., Strasser, A. and Adams, J. M.** (2014). Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. *Nat. Rev. Mol. Cell Biol.* **15**, 49-63. doi:10.1038/nrm3722
- Dammai, V. and Subramani, S.** (2001). The human peroxisomal targeting signal receptor, Pex5p, is translocated into the peroxisomal matrix and recycled to the cytosol. *Cell* **105**, 187-196. doi:10.1016/S0092-8674(01)00310-5
- de Duve, C. and Baudhuin, P.** (1966). Peroxisomes (microbodies and related particles). *Physiol. Rev.* **46**, 323-357. doi:10.1152/physrev.1966.46.2.323
- Delille, H. K., Agricola, B., Guimaraes, S. C., Borta, H., Lüers, G. H., Franssen, M. and Schrader, M.** (2010). Pex11p-mediated growth and division of mammalian peroxisomes follows a maturation pathway. *J. Cell Sci.* **123**, 2750-2762. doi:10.1242/jcs.062109
- Delmaghani, S., Defourny, J., Aghaie, A., Beurg, M., Dulon, D., Thelen, N., Perfettini, I., Zelles, T., Aller, M., Meyer, A. et al.** (2015). Hypervulnerability to sound exposure through impaired adaptive proliferation of peroxisomes. *Cell* **163**, 894-906. doi:10.1016/j.cell.2015.10.023
- Ebberink, M. S., Koster, J., Visser, G., van Spronsen, F., Stolte-Dijkstra, I., Smit, G. P. A., Fock, J. M., Kemp, S., Wanders, R. J. A. and Waterham, H. R.** (2012). A novel defect of peroxisome division due to a homozygous non-sense mutation in the *PEX11β* gene. *J. Med. Genet.* **49**, 307-313. doi:10.1136/jmedgenet-2012-100778
- Evrard, P., Caviness, V. S. J., Prats-Vinas, J. and Lyon, G.** (1978). The mechanism of arrest of neuronal migration in the Zellweger malformation: an hypothesis bases upon cytoarchitectonic analysis. *Acta Neuropathol.* **41**, 109-117. doi:10.1007/BF00689761
- Fagarasanu, A., Fagarasanu, M. and Rachubinski, R. A.** (2007). Maintaining peroxisome populations: a story of division and inheritance. *Annu. Rev. Cell Dev. Biol.* **23**, 321-344. doi:10.1146/annurev.cellbio.23.090506.123456
- Farré, J.-C., Mahalingam, S. S., Proietto, M. and Subramani, S.** (2019). Peroxisome biogenesis, membrane contact sites, and quality control. *EMBO Rep.* **20**, e46864. doi:10.15252/embr.201846864
- Faust, P. L.** (2003). Abnormal cerebellar histogenesis in *PEX2* Zellweger mice reflects multiple neuronal defects induced by peroxisome deficiency. *J. Comp. Neurol.* **461**, 394-413. doi:10.1002/cne.10699
- Faust, P. L. and Hatten, M. E.** (1997). Targeted deletion of the *PEX2* peroxisome assembly gene in mice provides a model for Zellweger syndrome, a human neuronal migration disorder. *J. Cell Biol.* **139**, 1293-1305. doi:10.1083/jcb.139.5.1293
- Fujiki, Y.** (2016). Peroxisome biogenesis and human peroxisome-deficiency disorders. *Proc. Jpn. Acad., Ser. B* **92**, 463-477. doi:10.2183/pjab.92.463
- Fujiki, Y., Itoyama, A., Abe, Y. and Honsho, M.** (2014a). Molecular complex coordinating peroxisome morphogenesis in mammalian cells. In *Molecular Machines Involved in Peroxisome Biogenesis and Maintenance* (ed. C. Brocard and A. Hartig), pp. 391-401. Berlin: Springer-Verlag.
- Fujiki, Y., Okumoto, K., Mukai, S., Honsho, M. and Tamura, S.** (2014b). Peroxisome biogenesis in mammalian cells. *Front. Physiol.* **5**, 307. doi:10.3389/fphys.2014.00307
- Fujiki, Y., Miyata, N., Mukai, S., Okumoto, K. and Cheng, E. H.** (2017). BAK regulates catalase release from peroxisomes. *Mol. Cell. Oncol.* **4**, e1306610. doi:10.1080/23723556.2017.1306610
- Furuki, S., Tamura, S., Matsumoto, N., Miyata, N., Moser, A., Moser, H. W. and Fujiki, Y.** (2006). Mutations in the peroxin Pex26p responsible for peroxisome biogenesis disorders of complementation group 8 impair its stability, peroxisomal localization, and interaction with the Pex1p-Pex6p complex. *J. Biol. Chem.* **281**, 1317-1323. doi:10.1074/jbc.M510044200
- Gandre-Babbe, S. and van der Blik, A. M.** (2008). The novel tail-anchored membrane protein Mff controls mitochondrial and peroxisomal fission in mammalian cells. *Mol. Biol. Cell* **19**, 2402-2412. doi:10.1091/mbc.e07-12-1287
- Goidfischer, S. and Reddy, J. K.** (1984). Peroxisomes (microbodies) in cell pathology. *Int. Rev. Exp. Pathol.* **26**, 45-84.
- Goldfischer, S., Moore, C. L., Johnson, A. B., Spiro, A. J., Valsamis, M. P., Wisniewski, H. K., Ritch, R. H., Norton, W. T., Rapin, I. and Gartner, L. M.** (1973). Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. *Science* **182**, 62-64. doi:10.1126/science.182.4107.62
- Heymans, H. S. A., Schutgens, R. B. H., Tan, R., van den Bosch, H. and Borst, P.** (1983). Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome). *Nature* **306**, 69-70. doi:10.1038/306069a0
- Honsho, M. and Fujiki, Y.** (2017). Plasmalogen homeostasis: regulation of plasmalogen biosynthesis and its physiological consequence in mammals. *FEBS Lett.* **591**, 2720-2729. doi:10.1002/1873-3468.12743
- Honsho, M., Yamashita, S. and Fujiki, Y.** (2016). Peroxisome homeostasis: mechanisms of division and selective degradation of peroxisomes in mammals. *Biochim. Biophys. Acta-Mol. Cell Res.* **1863**, 984-991. doi:10.1016/j.bbamcr.2015.09.032
- Hosoi, K., Miyata, N., Mukai, S., Furuki, S., Okumoto, K., Cheng, E. H. and Fujiki, Y.** (2017). The VDACC-BAK axis regulates peroxisomal membrane permeability. *J. Cell Biol.* **216**, 709-722. doi:10.1083/jcb.201605002
- Huber, N., Guimaraes, S., Schrader, M., Suter, U. and Niemann, A.** (2013). Charcot-Marie-Tooth disease-associated mutants of GDAP1 dissociate its roles in peroxisomal and mitochondrial fission. *EMBO Rep.* **14**, 545-552. doi:10.1038/embo.2013.56
- Imoto, Y., Abe, Y., Okumoto, K., Honsho, M., Kuroiwa, H., Kuroiwa, T. and Fujiki, Y.** (2017). Defining the dynamin-based ring organizing center on the peroxisome-dividing machinery isolated from *Cyanidioschyzon merolae*. *J. Cell Sci.* **130**, 853-867. doi:10.1242/jcs.199182
- Imoto, Y., Kuroiwa, H., Yoshida, Y., Ohnuma, M., Fujiwara, T., Yoshida, M., Nishida, K., Yagisawa, F., Hirooka, S., Miyagishima, S. Y. et al.** (2013). Single-membrane-bounded peroxisome division revealed by isolation of dynamin-based machinery. *Proc. Natl. Acad. Sci. USA* **110**, 9583-9588. doi:10.1073/pnas.1303483110
- Imoto, Y., Abe, Y., Honsho, M., Okumoto, K., Ohnuma, M., Kuroiwa, H., Kuroiwa, T. and Fujiki, Y.** (2018). Onsite GTP fuelling via DYNAMO1 drives division of mitochondria and peroxisomes. *Nat. Commun.* **9**, 4634. doi:10.1038/s41467-018-07009-z
- Imoto, Y., Abe, Y., Okumoto, K., Ohnuma, M., Kuroiwa, H., Kuroiwa, T. and Fujiki, Y.** (2019). Dynamics of nucleoside diphosphate kinase protein DYNAMO2 correlates with global GTP level during cell cycle of *Cyanidioschyzon merolae*. *Proc. Jpn. Acad. Ser. B* **95**, 75-85. doi:10.2183/pjab.95.007
- Itoyama, A., Honsho, M., Abe, Y., Moser, A., Yoshida, Y. and Fujiki, Y.** (2012). Docosahexaenoic acid mediates peroxisomal elongation, a prerequisite for peroxisome division. *J. Cell Sci.* **125**, 589-602. doi:10.1242/jcs.087452
- Itoyama, A., Michiyuki, S., Honsho, M., Yamamoto, T., Moser, A., Yoshida, Y. and Fujiki, Y.** (2013). Mff functions with Pex11p and DLP1 in peroxisomal fission. *Biol. Open* **2**, 998-1006. doi:10.1242/bio.20135298
- Kobayashi, S., Tanaka, A. and Fujiki, Y.** (2007). Fis1, DLP1, and Pex11p coordinately regulate peroxisome morphogenesis. *Exp. Cell Res.* **313**, 1675-1686. doi:10.1016/j.yexcr.2007.02.028
- Koch, J. and Brocard, C.** (2012). PEX11 proteins attract Mff and human Fis1 to coordinate peroxisomal fission. *J. Cell Sci.* **125**, 3813-3826. doi:10.1242/jcs.102178
- Koch, A., Yoon, Y., Bonekamp, N. A., McNiven, M. A. and Schrader, M.** (2005). A role for Fis1 in both mitochondrial and peroxisomal fission in mammalian cells. *Mol. Biol. Cell* **16**, 5077-5086. doi:10.1091/mbc.e05-02-0159
- Koch, J., Pranjik, K., Huber, A., Ellinger, A., Hartig, A., Kragler, F. and Brocard, C.** (2010). PEX11 family members are membrane elongation factors that coordinate peroxisome proliferation and maintenance. *J. Cell Sci.* **123**, 3389-3400. doi:10.1242/jcs.064907
- Lazarow, P. B. and Fujiki, Y.** (1985). Biogenesis of peroxisomes. *Annu. Rev. Cell Biol.* **1**, 489-530. doi:10.1146/annurev.cb.01.110185.002421
- Li, X. and Gould, S. J.** (2002). PEX11 promotes peroxisome division independently of peroxisome metabolism. *J. Cell Biol.* **156**, 643-651. doi:10.1083/jcb.200112028
- Li, X. and Gould, S. J.** (2003). The dynamin-like GTPase DLP1 is essential for peroxisome division and is recruited to peroxisomes in part by PEX11. *J. Biol. Chem.* **278**, 17012-17020. doi:10.1074/jbc.M212031200
- Li, X., Baumgart, E., Morrell, J. C., Jimenez-Sanchez, G., Valle, D. and Gould, S. J.** (2002). PEX11β deficiency is lethal and impairs neuronal migration but does not abrogate peroxisome function. *Mol. Cell. Biol.* **22**, 4358-4365. doi:10.1128/MCB.22.12.4358-4365.2002
- Matsumoto, N., Tamura, S. and Fujiki, Y.** (2003a). The pathogenic peroxin Pex26p recruits the Pex1p-Pex6p AAA ATPase complexes to peroxisomes. *Nat. Cell Biol.* **5**, 454-460. doi:10.1038/ncb982
- Matsumoto, N., Tamura, S., Furuki, S., Miyata, N., Moser, A., Shimozawa, N., Moser, H. W., Suzuki, Y., Kondo, N. and Fujiki, Y.** (2003b). Mutations in novel peroxin gene *PEX26* that cause peroxisome-biogenesis disorders of complementation group 8 provide a genotype-phenotype correlation. *Am. J. Hum. Genet.* **73**, 233-246. doi:10.1086/377004
- Maxwell, M., Bjorkman, J., Nguyen, T., Sharp, P., Finnie, J., Paterson, C., Tonks, I., Paton, B. C., Kay, G. F. and Crane, D. I.** (2003). *Pex13* inactivation in the mouse disrupts peroxisome biogenesis and leads to a Zellweger syndrome phenotype. *Mol. Cell. Biol.* **23**, 5947-5957. doi:10.1128/MCB.23.16.5947-5957.2003
- Minichiello, L. and Klein, R.** (1996). TrkB and TrkC neurotrophin receptors cooperate in promoting survival of hippocampal and cerebellar granule neurons. *Genes Dev.* **10**, 2849-2858. doi:10.1101/gad.10.22.2849
- Miyata, N. and Fujiki, Y.** (2005). Shuttling mechanism of peroxisome targeting signal type 1 receptor Pex5: ATP-independent import and ATP-dependent export. *Mol. Cell. Biol.* **25**, 10822-10832. doi:10.1128/MCB.25.24.10822-10832.2005
- Moser, H. W.** (1987). New approaches in peroxisomal disorders. *Dev. Neurosci.* **9**, 1-18. doi:10.1159/000111604
- Newmeyer, D. D. and Ferguson-Miller, S.** (2003). Mitochondria: releasing power for life and unleashing the machineries of death. *Cell* **112**, 481-490. doi:10.1016/S0092-8674(03)00116-8
- Okumoto, K., Misono, S., Miyata, N., Matsumoto, Y., Mukai, S. and Fujiki, Y.** (2011). Cysteine ubiquitination of PTS1 receptor Pex5p regulates Pex5p recycling. *Traffic* **12**, 1067-1083. doi:10.1111/j.1600-0854.2011.01217.x
- Platta, H. W. and Erdmann, R.** (2007). The peroxisomal protein import machinery. *FEBS Lett.* **581**, 2811-2819. doi:10.1016/j.febslet.2007.04.001



- Platta, H. W., Grunau, S., Rosenkranz, K., Girzalsky, W. and Erdmann, R. (2005). Functional role of the AAA peroxins in dislocation of the cycling PTS1 receptor back to the cytosol. *Nat. Cell Biol.* **7**, 817-822. doi:10.1038/ncb1281
- Platta, H. W., Brinkmeier, R., Reidick, C., Galiani, S., Clausen, M. P. and Eggeling, C. (2016). Regulation of peroxisomal matrix protein import by ubiquitination. *Biochim. Biophys. Acta - Mol. Cell Res.* **1863**, 838-849. doi:10.1016/j.bbamcr.2015.09.010
- Powers, J. M. and Moser, H. W. (1998). Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. *Brain Pathol.* **8**, 101-120. doi:10.1111/j.1750-3639.1998.tb00139.x
- Ratbi, I., Falkenberg, K. D., Sommen, M., Al-Sheqaih, N., Guoua, S., Vandeweyer, G., Urquhart, J. E., Chandler, K. E., Williams, S. G., Roberts, N. A. et al. (2015). Heimler syndrome is caused by hypomorphic mutations in the peroxisome-biogenesis genes *PEX1* and *PEX6*. *Am. J. Hum. Genet.* **97**, 535-545. doi:10.1016/j.ajhg.2015.08.011
- Schrader, M. and Fahimi, H. D. (2006). Growth and division of peroxisomes. *Int. Rev. Cytol.* **255**, 237-290. doi:10.1016/S0074-7696(06)55005-3
- Schrader, M., Bonekamp, N. A. and Islinger, M. (2012). Fission and proliferation of peroxisomes. *Biochim. Biophys. Acta.* **1822**, 1343-1357. doi:10.1016/j.bbadis.2011.12.014
- Schrader, M., Costello, J. L., Godinho, L. F., Azadi, A. S. and Islinger, M. (2016). Proliferation and fission of peroxisomes - An update. *Biochim. Biophys. Acta-Mol. Cell Res.* **1863**, 971-983. doi:10.1016/j.bbamcr.2015.09.024
- Schwartz, P. M., Borghesani, P. R., Levy, R. L., Pomeroy, S. L. and Segal, R. A. (1997). Abnormal cerebellar development and foliation in *BDNF*<sup>-/-</sup> mice reveals a role for neurotrophins in CNS patterning. *Neuron* **19**, 269-281. doi:10.1016/S0896-6273(00)80938-1
- Tait, S. W. G. and Green, D. R. (2010). Mitochondria and cell death: outer membrane permeabilization and beyond. *Nat. Rev. Mol. Cell Biol.* **11**, 621-632. doi:10.1038/nrm2952
- Tanaka, A., Kobayashi, S. and Fujiki, Y. (2006). Peroxisome division is impaired in a CHO cell mutant with an inactivating point-mutation in dynamin-like protein 1 gene. *Exp. Cell Res.* **312**, 1671-1684. doi:10.1016/j.yexcr.2006.01.028
- Tanaka, A. J., Okumoto, K., Tamura, S., Abe, Y., Hirsch, Y., Deng, L., Ekstein, J., Chung, W. K. and Fujiki, Y. (2019). A newly identified mutation in the *PEX26* gene is associated with a milder form of Zellweger spectrum disorder. *Cold Spring Harb. Mol. Case Stud.* **5**, a003483. doi:10.1101/mcs.a003483
- Tateishi, K., Okumoto, K., Shimozawa, N., Tsukamoto, T., Osumi, T., Suzuki, Y., Kondo, N., Okano, I. and Fujiki, Y. (1997). Newly identified Chinese hamster ovary cell mutants defective in peroxisome biogenesis represent two novel complementation groups in mammals. *Eur. J. Cell Biol.* **73**, 352-359.
- Thoms, S. and Erdmann, R. (2005). Dynamin-related proteins and Pex11 proteins in peroxisome division and proliferation. *FEBS J.* **272**, 5169-5181. doi:10.1111/j.1742-4658.2005.04939.x
- Thoms, S. and Gaertner, J. (2012). First *PEX11 $\beta$*  patient extends spectrum of peroxisomal biogenesis disorder phenotypes. *J. Med. Genet.* **49**, 314-316. doi:10.1136/jmedgenet-2012-100899
- Torvik, A., Torp, S., Kase, B. F., Ek, J., Skjeldal, O. and Stokke, O. (1988). Infantile Refsum's disease: a generalized peroxisomal disorder. Case report with postmortem examination. *J. Neurol. Sci.* **85**, 39-53. doi:10.1016/0022-510X(88)90034-2
- Volpe, J. J. and Adams, R. D. (1972). Cerebro-hepato-renal syndrome of Zellweger: an inherited disorder of neuronal migration. *Acta Neuropathol.* **20**, 175-198. doi:10.1007/BF00686900
- Walton, P. A., Brees, C., Lismont, C., Apanasets, O. and Fransen, M. (2017). The peroxisomal import receptor *PEX5* functions as a stress sensor, retaining catalase in the cytosol in times of oxidative stress. *Biochim. Biophys. Acta Mol. Cell Res.* **1864**, 1833-1843. doi:10.1016/j.bbamcr.2017.07.013
- Wang, X. (2001). The expanding role of mitochondria in apoptosis. *Genes Dev.* **15**, 2922-2933.
- Waterham, H. R. and Ebberink, M. S. (2012). Genetics and molecular basis of human peroxisome biogenesis disorders. *Biochim. Biophys. Acta Mol. Basis Dis.* **1822**, 1430-1441. doi:10.1016/j.bbadis.2012.04.006
- Waterham, H. R., Ferdinandusse, S. and Wanders, R. J. A. (2016). Human disorders of peroxisome metabolism and biogenesis. *Biochim. Biophys. Acta Mol. Cell Res.* **1863**, 922-933. doi:10.1016/j.bbamcr.2015.11.015
- Waterham, H. R., Koster, J., van Roermund, C. W. T., Mooyer, P. A. W., Wanders, R. J. A. and Leonard, J. V. (2007). A lethal defect of mitochondrial and peroxisomal fission. *N. Eng. J. Med.* **356**, 1736-1741. doi:10.1056/NEJMoa064436
- Weller, S., Gould, S. J. and Valle, D. (2003). Peroxisome biogenesis disorders. *Annu. Rev. Genomics Hum. Genet.* **4**, 165-211. doi:10.1146/annurev.genom.4.070802.110424
- Weller, S., Cajigas, I., Morrell, J., Obie, C., Steel, G., Gould, S. J. and Valle, D. (2005). Alternative splicing suggests extended function of *PEX26* in peroxisome biogenesis. *Am. J. Hum. Genet.* **76**, 987-1007. doi:10.1086/430637
- Yan, M., Rayapuram, N. and Subramani, S. (2005). The control of peroxisome number and size during division and proliferation. *Curr. Opin. Cell Biol.* **17**, 376-383. doi:10.1016/j.ceb.2005.06.003
- Yano, T., Oku, M., Akeyama, N., Itoyama, A., Yurimoto, H., Kuge, S., Fujiki, Y. and Sakai, Y. (2010). A novel fluorescent sensor protein for visualization of redox states in the cytoplasm and in peroxisomes. *Mol. Cell. Biol.* **30**, 3758-3766. doi:10.1128/MCB.00121-10
- Yoshida, Y., Niwa, H., Honsho, M., Itoyama, A. and Fujiki, Y. (2015). Pex11p mediates peroxisomal proliferation by promoting deformation of the lipid membrane. *Biol. Open* **4**, 710-721. doi:10.1242/bio.201410801
- Zellweger, H., Maertens, P., Superneau, D. and Wertelecki, W. (1988). History of the cerebrohepato-renal syndrome of Zellweger and other peroxisomal disorders. *Southern Med. J.* **81**, 357-364. doi:10.1097/00007611-198803000-00017
- Zhou, P., Porcionatto, M., Pilapil, M., Chen, Y., Choi, Y., Tolia, K. F., Bikoff, J. B., Hong, E. J., Greenberg, M. E. and Segal, R. A. (2007). Polarized signaling endosomes coordinate BDNF-induced chemotaxis of cerebellar precursors. *Neuron* **55**, 53-68. doi:10.1016/j.neuron.2007.05.030